Blockchain Registration Transaction Record

FDA Grants Orphan Drug Status to Soligenix's Dusquetide for Behçet's Disease

Soligenix receives FDA orphan drug designation for dusquetide treating Behçet's disease following successful phase 2a trial results showing efficacy and safety.

This development matters because Behçet's disease is a rare, chronic inflammatory disorder that causes painful oral and genital ulcers, skin lesions, and potentially serious complications affecting multiple organs. Current treatment options are limited and often inadequate. The FDA orphan drug designation accelerates development of promising therapies, potentially bringing relief to patients who have few effective treatments. For the biopharmaceutical industry, such designations encourage investment in rare disease research, driving innovation in areas that might otherwise be overlooked due to small patient populations. This represents hope for improved quality of life for Behçet's patients and advances the broader field of autoimmune disease treatment.